BioLargo, Inc. BLGO
$0.09
$0.00-1.97%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.08M | 5.61M | 7.77M | 10.81M | 14.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.08M | 5.61M | 7.77M | 10.81M | 14.05M |
| Cost of Revenue | 2.45M | 3.23M | 4.36M | 5.78M | 7.67M |
| Gross Profit | 1.63M | 2.38M | 3.41M | 5.03M | 6.38M |
| SG&A Expenses | 16.47M | 15.85M | 15.65M | 14.77M | 9.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.19M | 21.80M | 22.61M | 23.27M | 20.40M |
| Operating Income | -18.11M | -16.18M | -14.84M | -12.46M | -6.34M |
| Income Before Tax | -18.79M | -16.67M | -15.19M | -12.78M | -6.60M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.79 | -16.67 | -15.19 | -12.78 | -6.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 4.31M | 3.76M | 3.41M | 2.94M | 2.70M |
| Net Income | -14.49M | -12.91M | -11.78M | -9.84M | -3.90M |
| EBIT | -18.11M | -16.18M | -14.84M | -12.46M | -6.34M |
| EBITDA | -17.90M | -15.98M | -14.64M | -12.26M | -6.15M |
| EPS Basic | -0.05 | -0.04 | -0.04 | -0.03 | -0.01 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.02 | 0.00 |
| EPS Diluted | -0.05 | -0.04 | -0.04 | -0.03 | -0.01 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | 0.00 |
| Average Basic Shares Outstanding | 1.26B | 1.25B | 1.23B | 1.21B | 1.21B |
| Average Diluted Shares Outstanding | 1.26B | 1.25B | 1.23B | 1.21B | 1.21B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |